幹細胞治療の世界市場：タイプ別、細胞源別、治療用途別、エンドユーザー別-2025-2030年予測

幹細胞治療市場は、2023年に4億3,983万米ドルと評価され、2024年には4億9,323万米ドルに達すると予測され、CAGR 12.88%で成長し、2030年には10億2,744万米ドルに達すると予測されています。

幹細胞治療は、医療技術革新における変革的な領域を象徴しており、未分化細胞が体内の損傷した細胞や病気の細胞を置き換えるために使用され、パーキンソン病、糖尿病、心臓病などのさまざまな慢性疾患の治療法の可能性を提供します。幹細胞治療の必要性は、複雑でこれまで治療不可能であった病態をターゲットとすることで、アンメット・メディカル・ニーズに対応できることにあり、再生医療における革命的なアプローチとなっています。最終用途は病院、研究機関、専門クリニックにまたがり、治療範囲は腫瘍学から脊髄治療まで多岐にわたる。この市場を大きく牽引しているのは、幹細胞研究における技術的進歩、慢性疾患の蔓延につながる高齢化、官民両部門からの投資拡大といった要因です。個別化医療が受け入れられつつあり、再生治療が回復期間を短縮し、生活の質を高める可能性があることから、チャンスは豊富です。しかし、胚性幹細胞の使用をめぐる倫理的懸念、高額な治療費、厳しい規制の枠組みは、依然として市場成長に対する顕著な課題です。また、治療結果のばらつきや長期にわたる臨床試験の複雑さといった限界もあります。市場機会を活かし、これらの制約を緩和するために、技術革新は費用対効果の高い同種細胞治療法の開拓と、自家幹細胞応用の最適化に焦点を当てるべきです。凍結保存技術の向上や細胞分化プロセスの改善など、さらなる調査が必要です。バイオテクノロジー企業、学術機関、政府機関が協力し合うことで、画期的な進歩を遂げるためのエコシステムが形成される。さらに、教育キャンペーンを通じて一般の人々の認識と受容を高めることで、倫理的な懸念が緩和され、市場浸透が促進される可能性があります。全体として、市場情勢は、持続的な発展のための戦略的アプローチが必要となる規制状況、倫理的、技術的課題によって緩和された、大きな成長の可能性に支えられたダイナミックな状況を示しています。

市場力学：急速に進化する幹細胞治療市場の主要市場インサイトを公開

幹細胞治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の変性疾患およびがん患者の増加
  • 世界各国における幹細胞治療に対する政府の取り組みの増加
  • 幹細胞治療センターおよびクリニックの拡大
• 市場抑制要因
  • 幹細胞治療の実施に伴う困難
• 市場機会
  • 幹細胞治療の継続的な進歩
  • 幹細胞治療や治療の販売承認や臨床試験の急増
• 市場の課題
  • 幹細胞を用いた治療の倫理的安全性の問題

ポーターのファイブフォース：幹細胞治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：幹細胞治療市場における外部からの影響の把握

外部マクロ環境要因は、幹細胞治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析幹細胞治療市場における競合情勢の把握

幹細胞治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス幹細胞治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、幹細胞治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で変性疾患やがんの罹患率が上昇
    • 世界中で幹細胞治療に関する政府の取り組みが増加
    • 幹細胞治療センターとクリニックの拡張
  • 抑制要因
    • 幹細胞治療の実行に伴う困難
  • 機会
    • 幹細胞治療の継続的な進歩
    • 幹細胞療法および治療法の販売および臨床試験の承認が急増
  • 課題
    • 幹細胞療法の倫理的および安全性の問題
• 市場セグメンテーション分析
  • タイプ：慢性疾患治療における同種および自家移植幹細胞治療の使用増加
  • Cell Source：組織リモデリングと組織修復におけるAD-MSCとBM-MSCの採用増加
  • 治療への応用：さまざまな治療領域で再生医療の人気が高まっている
  • エンドユーザー：効果的で安全かつ標準化された治療結果を提供する学術研究センターや病院での幹細胞治療の使用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 幹細胞治療市場：タイプ別

• 同種異系幹細胞治療
• 自家幹細胞治療

第7章 幹細胞治療市場セルソース

• 脂肪組織由来MSC
• 骨髄由来MSC
• 胎盤/臍帯由来MSC

第8章 幹細胞治療市場治療用途別

• 心臓血管疾患の手術
• 炎症性疾患および自己免疫疾患
• 筋骨格障害
• 神経疾患
• 整形外科とリウマチ
• 傷と負傷

第9章 幹細胞治療市場：エンドユーザー別

• 学術研究センター
• 外来手術センター
• バイオテクノロジーおよび製薬会社
• 病院・クリニック

第10章 南北アメリカの幹細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の幹細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの幹細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 富士フイルム、細胞治療の生産に2億米ドルを投資
  • メソブラスト、FDAの拒否後SR-aGVHD試験の協力を開始
  • セレクタ・バイオサイエンス、カルテシアン・セラピューティクスとの合併を発表
  • タカラバイオ、Fondazione Telethon ETSとレトロネクチンのライセンス契約を締結
  • バイエル、世界規模で再生医療を推進するため初の細胞治療製造施設を開設
  • ノボノルディスク財団、細胞治療工場建設に1億3,500万米ドルを投資
  • BioLineRx社は、多発性骨髄腫患者の造血幹細胞の採取とその後の自家移植を目的としたフィルグラスチム（G-CSF）との併用によるAPHEXDA（モチキサフォルチド）のFDA承認を発表
  • BlueRock Therapeuticsとbit.bioが、制御性T細胞（Treg）ベースの治療法の発見と製造に関する提携およびオプション契約を発表
  • StemCyte、最先端の米国免疫細胞療法企業と協力契約を締結し、同種改変細胞療法用の医薬品製造原料を供給
  • CIRM、幹細胞および遺伝子治療調査に8,900万米ドルを投資
  • ブリストルマイヤーズスクイブ、ウイルスベクター生産のための米国新製造施設の開設により細胞治療能力を強化
  • ノボノルディスク、グレーターボストン地域での研究開発拠点を拡大
  • ガルーダ・セラピューティクス、既製の血液幹細胞技術プラットフォームの発展に向けて6,200万米ドルのシリーズB資金調達を確保
  • BioCardiaとCellProtheraは、欧州での急性心筋梗塞治療のためのProtheraCytesの開発と患者への早期アクセスの可能性に向けて協力関係を強化
  • ReLive Biotechnologies Ltd.がCo.Don AGの資産買収とSHC主導のシリーズ A資金調達を完了し、再生療法の世界プレーヤーになるという野心をさらに推進

企業一覧

• 4D Molecular Therapeutics, Inc.
• Anterogen Co., Ltd.
• Astellas Pharma Inc.
• Athersys, Inc.
• Aurion Biotechnologies
• Beike Biotechnology Co., Ltd.
• BrainStorm Cell Therapeutics Inc.
• Bristol-Myers Squibb Company
• CellProthera
• Fate Therapeutics, Inc.
• Gamida Cell Ltd.
• Garuda Therapeutics
• Holostem Terapie Avanzate S.r.l.
• Jasper Therapeutics, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Juvena Therapeutics Inc.
• Kangstem Biotech., Ltd.
• Kite Pharma, Inc. by Gilead Sciences, Inc.
• Lineage Cell Therapeutics, Inc.
• Lonza Group AG
• Mesoblast Ltd.
• Novo Nordisk A/S
• Plasticell
• ReNeuron Group PLC
• Sartorius CellGenix GmbH
• SQZ Biotechnologies Company
• Takara Bio Inc.
• U.S. Stem Cell Inc
• Umoja Biopharma
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 63. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 67. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 136. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 152. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 156. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Stem Cell Therapy Market was valued at USD 439.83 million in 2023, expected to reach USD 493.23 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,027.44 million by 2030.

Stem cell therapy represents a transformative area in medical innovation, where undifferentiated cells are used to replace damaged or diseased cells in the body, offering potential cures for various chronic illnesses such as Parkinson's, diabetes, and heart diseases. The necessity for stem cell therapy arises from its ability to address unmet medical needs by targeting complex and previously untreatable conditions, making it a revolutionary approach in regenerative medicine. Applications range from oncology to spinal cord treatments, with end-use spanning across hospitals, research institutes, and specialized clinics. The market is significantly driven by factors such as technological advancements in stem cell research, an aging population leading to increased prevalence of chronic conditions, and growing investments from both public and private sectors. Opportunities are abundant with the increasing acceptance of personalized medicine and the potential for regenerative treatments to shorten recovery times and enhance life quality. However, ethical concerns surrounding embryonic stem cell use, high treatment costs, and stringent regulatory frameworks remain prominent challenges to market growth. Limitations also include variability in treatment outcomes and the complexity of long-term clinical trials. To capitalize on market opportunities and mitigate these constraints, innovation should focus on developing cost-effective allogenic treatments and optimizing autologous stem cell applications. Further research is warranted in enhancing cryopreservation techniques and improving cell differentiation processes. Collaborations between biotech firms, academic institutions, and government bodies can foster an ecosystem primed for breakthroughs. Moreover, increasing public awareness and acceptance through educational campaigns could alleviate ethical concerns and drive market penetration. Overall, the stem cell therapy market presents a dynamic landscape underpinned by significant growth potential tempered by regulatory, ethical, and technical challenges that necessitate strategic approaches for sustained advancement.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stem Cell Therapy Market

The Stem Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of degenerative diseases and cancer cases across the world
  • Increasing government initiatives for stem cell therapy across the world
  • Expansion of stem cell therapy centers and clinics
• Market Restraints
  • Difficulties associated with performing stem cell therapy
• Market Opportunities
  • Ongoing advancements in stem cell therapy
  • Surging approvals for marketing and clinical trials for stem cell therapies and treatments
• Market Challenges
  • Ethical and safety issues of stem cell-based therapy

Porter's Five Forces: A Strategic Tool for Navigating the Stem Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stem Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stem Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stem Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stem Cell Therapy Market

A detailed market share analysis in the Stem Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stem Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stem Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
• Based on Cell Source, market is studied across Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, and Placental / Umbilical Cord-Derived MSCs.
• Based on Therapeutic Application, market is studied across Cardiovascular Diseases Surgeries, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Orthopedics & Rheumatoid, and Wounds & Injuries.
• Based on End-User, market is studied across Academic & Research Centers, Ambulatory Surgical Centers, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
    • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
    • 5.1.1.3. Expansion of stem cell therapy centers and clinics
  • 5.1.2. Restraints
    • 5.1.2.1. Difficulties associated with performing stem cell therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in stem cell therapy
    • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
  • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
  • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
  • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Type

• 6.1. Introduction
• 6.2. Allogeneic Stem Cell Therapy
• 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

• 7.1. Introduction
• 7.2. Adipose Tissue-Derived MSCs
• 7.3. Bone Marrow-Derived MSCs
• 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases Surgeries
• 8.3. Inflammatory & Autoimmune Diseases
• 8.4. Musculoskeletal Disorders
• 8.5. Neurological Disorders
• 8.6. Orthopedics & Rheumatoid
• 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Centers
• 9.3. Ambulatory Surgical Centers
• 9.4. Biotechnology & Pharmaceutical Companies
• 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
  • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
  • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
  • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
  • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
  • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
  • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
  • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
  • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
  • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
  • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
  • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
  • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
  • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

Companies Mentioned

• 1. 4D Molecular Therapeutics, Inc.
• 2. Anterogen Co., Ltd.
• 3. Astellas Pharma Inc.
• 4. Athersys, Inc.
• 5. Aurion Biotechnologies
• 6. Beike Biotechnology Co., Ltd.
• 7. BrainStorm Cell Therapeutics Inc.
• 8. Bristol-Myers Squibb Company
• 9. CellProthera
• 10. Fate Therapeutics, Inc.
• 11. Gamida Cell Ltd.
• 12. Garuda Therapeutics
• 13. Holostem Terapie Avanzate S.r.l.
• 14. Jasper Therapeutics, Inc.
• 15. JCR Pharmaceuticals Co., Ltd.
• 16. Juvena Therapeutics Inc.
• 17. Kangstem Biotech., Ltd.
• 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
• 19. Lineage Cell Therapeutics, Inc.
• 20. Lonza Group AG
• 21. Mesoblast Ltd.
• 22. Novo Nordisk A/S
• 23. Plasticell
• 24. ReNeuron Group PLC
• 25. Sartorius CellGenix GmbH
• 26. SQZ Biotechnologies Company
• 27. Takara Bio Inc.
• 28. U.S. Stem Cell Inc
• 29. Umoja Biopharma
• 30. Vericel Corporation